Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 12 years, it is emailed daily to more than 10,000 pharma industry professionals throughout Australia and NZ.

For just $429.95 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or admin@pharmainfocus.com.au for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Special Report
Digital transformation in pharma - what's it look like?
If digital is the future for pharma businesses then getting there will call for change from the top down writes Tania Rowland.
Approvals Action
Baxalta registers new haemophilia treatment
Shire-owned Baxalta has won TGA approval for a new haemophilia A treatment under the brand name Adynovate.
Pipeline Monitor
First Parkinson's drug in a decade wins US tick
Parkinson's disease patients now have something to turn to in the 'off' period when their standard medication loses effectiveness.
Debating Point
Resources in question as TGA modernises
Most areas of the pharmaceutical sector appear to agree that modernising the TGA is a good thing but how much pressure the new requirements will place on the regulator's resources remains an issue.